Bimatoprost lash serum

Compounded bimatoprost 0.03% lash serum for short or sparse eyelashes, after a licensed provider's review. A licensed 503A compounding pharmacy prepares your order and ships it free.

Bimatoprost lash serum paid once: $229 for 1 month, $618 for 3 months, $1,168 for 6 months or $2,198 for 12 months. With auto-refill each is 10% off: $206, $556, $1,051 and $1,978 ($164.83 a month on the 12-month plan). Shipping is free, and the exact total is shown before you pay.

Yes. You complete an online health intake, including your eye history, and a licensed provider decides whether bimatoprost is right for you. Choosing a plan does not guarantee a prescription.

Bimatoprost 0.03% is an FDA-approved drug as Latisse: Drugs@FDA lists LATISSE as bimatoprost 0.03% solution/drops for topical use by prescription, with an ORIG-1 action dated 12/24/2008. The serum sold here is compounded by a licensed 503A pharmacy. FDA says compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed. The label and trial results on this site come from the approved product.

The Latisse FDA label says the precise mechanism of action is unknown and that the growth of eyelashes is believed to occur by increasing the percent of hairs in, and the duration of, the anagen or growth phase.

The Latisse label says to apply nightly directly to the skin of the upper eyelid margin at the base of the eyelashes, to blot any excess solution beyond the eyelid margin, and to use a new sterile applicator for each eyelid. It says not to apply in the eye or to the lower lid, and that contact lenses should be removed before application and may be reinserted 15 minutes later. Your provider and pharmacy label give the directions for your serum.

The Latisse label's patient counseling section says the onset of effect is gradual but is not significant in the majority of patients until 2 months. The label says that upon discontinuation of treatment, eyelash growth is expected to return to its pre-treatment level, and its patient information says the eyelashes are expected to return to their previous appearance over several weeks to months.

The Latisse label lists eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms and periorbital erythema among the most frequently reported adverse reactions in its clinical trial. Its postmarketing section lists periorbital and lid changes associated with periorbital fat atrophy and skin tightness resulting in deepening of eyelid sulcus and eyelid ptosis, and says these reports are voluntary from a population of uncertain size, so it is not always possible to reliably estimate their frequency or establish a causal relationship. Your provider explains what applies to you.

The Latisse label says increased iris pigmentation has occurred when bimatoprost solution was administered and that the brown iris pigmentation is likely to be permanent. It says iris color changes may not be noticeable for several months to years. In an observational retrospective chart review of cutaneous application, with the concentration not stated, no iris pigmentation change was noted.

The Latisse label's patient counseling section says the product may lower intraocular pressure although not to a level that will cause clinical harm, and that patients using prostaglandin analogs for IOP reduction should only use it after consulting with their physician and should be monitored for changes to their intraocular pressure. The patient information says that if you have a history of abnormal IOP, you should only use it under the close supervision of your physician.

The Latisse label's pregnancy section states that the 0.03% product should be administered during pregnancy only if the potential benefit justifies the potential risk to the fetus, and says there are no adequate and well-controlled studies in pregnant women. It says it is not known whether topical ocular treatment could result in sufficient systemic absorption to produce detectable quantities in human milk.

The FDA says section 503A of the FD&C Act describes the conditions under which compounded human drug products are exempt from the FD&C Act sections on FDA approval prior to marketing, current good manufacturing practice (CGMP) requirements, and labeling with adequate directions for use. One of the section 503A conditions is that the drugs must be compounded based on the receipt of valid patient-specific prescriptions. FDA also says compounded drugs are not FDA approved.

No. You can pay once for 1, 3, 6 or 12 months, or turn on auto-refill and take 10% off. You can change or cancel refills anytime.